The main findings of this study were that co-prescribing aripiprazole not only had no clinical value in reducing PRL levels in the target population of our study but also increased the severity of metabolic disorders compared to the clinical subgroup without co-prescribing aripiprazole. The gene discussed is PRL; the disease is metabolic disease.